~~<i id='43CDC50190'><strike id='43CDC50190'><tt id='43CDC50190'><pre id='43CDC50190'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

focus

author：knowledge 2025-08-12 09:09:44 - browse：552

Editor’s note: A recording of the event is embedded below.

After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

Featured Speakers

Irena Melnikova, Ph.D., partner, Pfizer Ventures
Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Roche to buy Carmot Therapeutics, developer of obesity drugs

hotspot

leisure time

focus

leisure time

hotspot

SammyKimballforSTATAredrugpricesprotectedbytheConstitution?WillMedicareembraceAlzheimer’sdiseasetrea

WSS

FDA approves world's first CRISPR

Why failed clinical trials don’t always spell doom for a new drug

Anavex keeps shifting the goalposts in its clinical trials

What PEPFAR has meant on the ground in Ukraine

CMS should re

Police still searching for prisoner who escaped from NYC hospital

hotspot

focus

Featured Speakers

hotspot

Alkermes shareholders re

Drastic changes should bring profitability, startup health insurers say

In age of alternative facts, a scholarly course on calling out crap

How to use technology to prevent future drug shortages

BioMarin wins approval for gene therapy to treat hemophilia A

In diabetes hearing, Sanders takes on a new foe: food makers

Hepatitis C has a cure — but many Americans still lack access to it

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

23andMe had bad news about my health. I wish a person had delivered it

Americans' trust in science, scientist continues decline: Report

leisure time

Maui's cultural, historic landmarks damaged in the devastating wildfires

Police still searching for prisoner who escaped from NYC hospital

Shkreli is convicted of fraud. Can pharma finally slam the door on him?

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

In same hospitals, Black patients receive fewer opioids than white patients

Why failed clinical trials don’t always spell doom for a new drug

focus

focus

leisure time

hotspot